Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Director Jack W. Schuler acquired 61,300 shares of the firm’s stock in a transaction dated Friday, October 13th. The shares were purchased at an average cost of $19.29 per share, for a total transaction of $1,182,477.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) opened at 20.60 on Wednesday. The stock’s market cap is $1.14 billion. The company’s 50-day moving average price is $22.49 and its 200 day moving average price is $25.49. Accelerate Diagnostics, Inc. has a 12-month low of $18.35 and a 12-month high of $30.45.

Accelerate Diagnostics (NASDAQ:AXDX) last announced its quarterly earnings data on Thursday, August 3rd. The medical research company reported ($0.31) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.01). Accelerate Diagnostics had a negative return on equity of 67.44% and a negative net margin of 5,062.48%. The company had revenue of $0.70 million for the quarter, compared to analysts’ expectations of $1.40 million. On average, equities analysts predict that Accelerate Diagnostics, Inc. will post ($1.20) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Accelerate Diagnostics, Inc. (AXDX) Director Jack W. Schuler Purchases 61,300 Shares” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/accelerate-diagnostics-inc-axdx-director-jack-w-schuler-purchases-61300-shares/1638110.html.

A number of institutional investors have recently made changes to their positions in the stock. Intl Fcstone Inc. purchased a new position in Accelerate Diagnostics during the second quarter worth approximately $322,000. Verition Fund Management LLC purchased a new position in Accelerate Diagnostics during the second quarter worth approximately $343,000. California State Teachers Retirement System lifted its position in Accelerate Diagnostics by 1.5% during the second quarter. California State Teachers Retirement System now owns 46,111 shares of the medical research company’s stock worth $1,261,000 after buying an additional 700 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Accelerate Diagnostics by 13.0% during the second quarter. The Manufacturers Life Insurance Company now owns 21,125 shares of the medical research company’s stock worth $578,000 after buying an additional 2,425 shares in the last quarter. Finally, State Street Corp lifted its position in Accelerate Diagnostics by 12.5% during the second quarter. State Street Corp now owns 475,078 shares of the medical research company’s stock worth $12,993,000 after buying an additional 52,817 shares in the last quarter. Hedge funds and other institutional investors own 44.43% of the company’s stock.

Several brokerages have recently issued reports on AXDX. ValuEngine cut Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. BidaskClub cut Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. Zacks Investment Research lowered Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. Finally, BTIG Research restated a “buy” rating and set a $34.00 price target on shares of Accelerate Diagnostics in a report on Wednesday, July 12th. Three equities research analysts have rated the stock with a sell rating and two have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $33.00.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Insider Buying and Selling by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.